tradingkey.logo

Phathom Pharmaceuticals Inc <PHAT.OQ> expected to post a loss of $1.15 a share - Earnings Preview

ReutersApr 29, 2025 12:45 PM
  • Phathom Pharmaceuticals Inc PHAT.OQ PHAT.O is expected to show a rise in quarterly revenue when it reports results on May 1 for the period ending March 31 2025

  • The Florham Park New Jersey-based company is expected to report a 1,417.6% increase in revenue to $29.016 million from $1.91 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Phathom Pharmaceuticals Inc is for a loss of $1.15 per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts had risen by about 0.3% in the last three months. ​

  • Wall Street's median 12-month price target for Phathom Pharmaceuticals Inc is $21.00​, above​ its last closing price of $4.15. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-1.31

-1.27

-1.05

Beat

17.4

Sep. 30 2024

-1.59

-1.49

-1.32

Beat

11.7

Jun. 30 2024

-1.40

-1.38

-1.56

Missed

-13​

Mar. 31 2024

-1.28

-1.31

-1.42

Missed

-8.5

​​Dec. 31 2023

-1.10

-1.08

-1.39

Missed

-29.1

Sep. 30 2023

-0.87

-0.89

-0.76

Beat

14.7​

Jun. 30 2023

-0.94

-0.98

-0.84

Beat

14.2

Mar. 31 2023

-1.23

-1.26

-0.89

Beat

29.4

This summary was machine generated April 29 at 12:44 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI